<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48654">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992328</url>
  </required_header>
  <id_info>
    <org_study_id>MED-CT4-12-405</org_study_id>
    <nct_id>NCT01992328</nct_id>
  </id_info>
  <brief_title>IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency</brief_title>
  <acronym>IVIG</acronym>
  <official_title>IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin G deficiency subtypes in patients with asthma six months once a month
      intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on
      reducing the frequency of asthma exacerbations appreciate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients Registration

      •It is required to ensure that the patients meet the inclusion criteria for this clinical
      trial, are free from any items of exclusion criteria, are explained about the participation
      in the clinical trial along with the informed consent forms.

      Procedure

      •six months once a month intravenous immunoglobulin (400mg/kg/4weeks)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Infection rate</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 months after treatment compared to before treatment 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung funtion</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Lung function (FEV1) compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>steroid</measure>
    <time_frame>6 months af</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Systemic steroid dose and the number of uses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotic</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- The frequency and duration of antibiotic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma syptoms</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- The frequency of asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Asthma Quality of Life (AQOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnair</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Asthma control score (K-ACT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG subclass</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Before and after treatment serum IgG subclass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Cytokines serum levels before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>- The frequency of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Immune Globulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoglobulin G Deficiency Associated with persistent asthma subtypes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin</intervention_name>
    <description>6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)</description>
    <arm_group_label>Immune Globulin</arm_group_label>
    <other_name>Immunoglobulin G Deficiency</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient from over 16 years to under 75 years

          -  Patients diagnosed with asthma over six months ago

          -  immunoglobulin G subtypes who were diagnosed with immune deficiency

          -  more than 2 years Upper and lower respiratory tract infections

             , and asthma exacerbations in this regard.

          -  ① calculated creatinine clearance ≧ 50ml/min

               -  ALT and AST &lt;x 3 times the upper limit of normal

                    -  ALP &lt;x 3 times the upper limit of normal

                         -  total bilirubin &lt;x 1.5 times the upper limit of normal

        Exclusion Criteria:

          -  within six months of the onset of the experiment who received immunoglobulin therapy

          -  immune globulin for those with a history of hypersensitivity reactions

          -  six months ago, another clinical trial participants.

          -  Systemic steroids and immunomodulators, such as asthma control that may affect the
             resources required drug administration.

          -  pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hae-sim park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medicine, Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yun-kyoung KIM</last_name>
    <phone>82-31-219-4467</phone>
    <email>FORSAKE326@ajou.ac.kr</email>
  </overall_contact>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hae-Sim Park</investigator_full_name>
    <investigator_title>Professor, Department of medicine, Ajou University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Immunoglobulin G Deficiency</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>IgG Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
